Valeant's new chief cuts a familiar figure
Joseph Papa pursued a series of strategies at Perrigo that were similar to the drugmaker's discredited business model
Add BT as a preferred source
DeeperDive is a beta AI feature. Refer to full articles for the facts.
New York
WHEN a deeply troubled company replaces its chief executive, it makes sense to expect the new CEO to bring a fresh take to its operations. A clean sweep, so to speak.
But if shareholders in Valeant Pharmaceuticals International envisage a vastly different approach by Joseph Papa, the company's incoming chief executive, they may be disappointed. That's because in the almost 10 years that Mr Papa headed Perrigo Co, a maker and distributor of over-the-counter and generic prescription drugs, the company pursued a series of strategies that were very Valeant-esque.
Share with us your feedback on BT's products and services
TRENDING NOW
Shelving S$5 billion office redevelopment plan proved ‘wise’ as geopolitical risks mount: OCBC chairman
OCBC is said to emerge as lead bidder for HSBC Indonesia assets
Middle East-linked energy supply shocks put Asean Power Grid back in focus
Eurokars Group introduces rental car franchises Enterprise Rent-A-Car, National Car Rental, and Alamo to Singapore
